Literature DB >> 33817653

Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy.

Helaina C Regen-Tuero1, Robert C Ward1, William M Sikov1, Peter J Littrup1.   

Abstract

Cryoablation is a well-tolerated outpatient procedure that has been used to treat metastatic sites as well as small breast cancers in patients who are considered poor candidates for surgery. Recent studies suggest that cell disruption caused by cryoablation may increase the expression and immunogenicity of tumor neoantigens, which could enhance the ability of the immune system to recognize and attack cancer cells at both local and distant sites. Such an approach might broaden the role of immunotherapy for the treatment of breast cancer, which has previously demonstrated limited response to these agents, likely owing to the modest immunogenicity of most breast cancer subtypes. If cryoablation can induce a systemic tumor-specific response, it could enhance tumor susceptibility to immunotherapy agents. This review briefly summarizes the necessary components for generating an immune response against tumor cells, reviews the tumor microenvironment of breast cancer, describes the rationale for and limitations of immune checkpoint inhibition, highlights the potential for cryoablation to induce a systemic tumor-specific immune response, and describes the rationale for combining cryoablation and immune checkpoint inhibitors for the treatment of breast cancer. Keywords: Ablation Techniques, Breast, Neoplasms-Primary, Percutaneous, Tumor Microenvironment, Tumor Response, Ultrasonography © RSNA, 2021. 2021 by the Radiological Society of North America, Inc.

Entities:  

Keywords:  Ablation Techniques; Breast; Neoplasms-Primary; Percutaneous; Tumor Microenvironment; Tumor Response; Ultrasonography

Year:  2021        PMID: 33817653      PMCID: PMC8011444          DOI: 10.1148/rycan.2021200134

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  52 in total

1.  Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.

Authors:  Robert H Vonderheide; Patricia M LoRusso; Magi Khalil; Elaina M Gartner; Divis Khaira; Denis Soulieres; Prudence Dorazio; Jennifer A Trosko; Jens Rüter; Gabriella L Mariani; Tiziana Usari; Susan M Domchek
Journal:  Clin Cancer Res       Date:  2010-05-17       Impact factor: 12.531

2.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Ultrasound-Guided Breast Cancer Cryoablation.

Authors:  Robert C Ward; Ana P Lourenco; Martha B Mainiero
Journal:  AJR Am J Roentgenol       Date:  2019-05-23       Impact factor: 3.959

Review 4.  Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.

Authors:  Katherine Sanchez; David Page; Heather L McArthur
Journal:  Curr Probl Cancer       Date:  2016-09-26       Impact factor: 3.187

5.  Immunologic response to cryoablation of breast cancer.

Authors:  Michael S Sabel; Matthew A Nehs; Gang Su; Kathleen P Lowler; James L M Ferrara; Alfred E Chang
Journal:  Breast Cancer Res Treat       Date:  2005-03       Impact factor: 4.872

6.  Changes in interleukin-1β and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections.

Authors:  Fateh Ahmad; Gianpiero Gravante; Neil Bhardwaj; Andrew Strickland; Rizwan Basit; Kevin West; Roberto Sorge; Ashley R Dennison; David M Lloyd
Journal:  Am J Surg       Date:  2010-10       Impact factor: 2.565

7.  Hepatic cryoablation, but not radiofrequency ablation, results in lung inflammation.

Authors:  W C Chapman; J P Debelak; C Wright Pinson; M K Washington; J B Atkinson; A Venkatakrishnan; T S Blackwell; J W Christman
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

8.  Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Authors:  Leisha A Emens; Cristina Cruz; Joseph Paul Eder; Fadi Braiteh; Cathie Chung; Sara M Tolaney; Irene Kuter; Rita Nanda; Philippe A Cassier; Jean-Pierre Delord; Michael S Gordon; Ehab ElGabry; Ching-Wei Chang; Indrani Sarkar; William Grossman; Carol O'Hear; Marcella Fassò; Luciana Molinero; Peter Schmid
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

Review 9.  Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?

Authors:  Amol Mehta; Rahmi Oklu; Rahul A Sheth
Journal:  Gastroenterol Res Pract       Date:  2016-03-08       Impact factor: 2.260

Review 10.  Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.

Authors:  Paula García-Teijido; María Luque Cabal; Ignacio Peláez Fernández; Yolanda Fernández Pérez
Journal:  Clin Med Insights Oncol       Date:  2016-04-05
View more
  2 in total

1.  ASO Author Reflections: Cryoablation Cost-Benefit Analysis: Managing Breast Cancer Through Cost-Effective Therapy.

Authors:  Sonia Y Khan; Michael W Melkus; Rakhshanda Layeequr Rahman
Journal:  Ann Surg Oncol       Date:  2022-10-16       Impact factor: 4.339

2.  Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.

Authors:  Xin Li; Jiahua Xu; Xiaoqiang Gu; Ling Chen; Qing Wu; Hongwei Li; Haoran Bai; Jinzu Yang; Jianxin Qian
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.